Elizabeth Hess has broad experience representing clients in government enforcement defense and internal investigations, and in a variety of litigation matters. She defends corporations and corporate executives in government investigations and other criminal and regulatory proceedings in connection with various allegations. She also leads internal investigations for a variety of clients and counsels clients on the adequacy of their internal controls and compliance policies and procedures.
Elizabeth has also acted as trial, appellate, and arbitration counsel in both individual and class action suits involving claims in various practice areas, including state and federal False Claims Act liability, complex commercial disputes, unfair and deceptive trade practices, consumer fraud, securities and shareholder class actions, and professional liability involving auditors/accountants, architects, engineers and contractors.
Represent pharmaceutical and medical device companies and other healthcare institutions in healthcare fraud investigations conducted by federal and state enforcement agencies involving pricing issues, allegations of off-label promotion, improper sales and marketing practices, and alleged violations of the False Claims Act and the Anti-Kickback Statute.
Represent medical device manufacture in qui tam litigation pending in Texas regarding the alleged off-label promotion of a medical device.
Represent pharmaceutical company in qui tam litigation pending in Pennsylvania regarding the alleged off-label promotion of a prescription drug and other alleged improper sales and marketing practices.
Represented pharmaceutical company in qui tam litigation pending in Ohio regarding the alleged off-label and improper promotion of several prescription drugs and other alleged improper sales and marketing practices.
Represented pharmaceutical manufacturers in various actions brought in state and federal courts on behalf of state Medicaid agencies and the federal government asserting that prescription pharmaceutical manufacturers reported inaccurate pricing benchmarks, allegedly causing the states and federal government to overpay providers for drugs dispensed to Medicaid and Medicare beneficiaries.
Named to The Legal 500 U.S. for Securities: Shareholder Litigation in 2014. Clients say she is "very responsive" and "very bright."
Named an "Illinois Rising Star" by Super Lawyers magazine in 2010, 2011 and 2012.
Comment, Administrative Exhaustion Requirements and Class Actions: Rules, Rights, Requirements, Remedies, and the Prison Litigation Reform Act Issue Resolved, 2003 U. Chi. Legal F. 773
PILI Fellow, MacArthur Justice Center, University of Chicago Law School, Chicago, Illinois, 06/04-09/04; Law Clerk, MacArthur Justice Center, 06/02-09/02